Circadian Variation of Fibrinolytic Activity in Blood

References

• Astrup T. The biological significance of fibrinolysis. Lancet 1956;2:565–8.
   Google Scholar
• Bachmann F. Fibrinolysis. In: Verstraete M, Vermylen J, Leijnen L, Arnout J, eds. Thrombosis and huemostusis. Leuven: Leuven University Press, 1987:227–65.
   Google Scholar
• Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381–7.
   PubMed Web of Science ®Google Scholar
• Fearnley GR. Fibrinolysis. London: Edward Arnold Ltd., 1965:28–44.
   Google Scholar
• Fearnley GR, Balmforth G, Fearnley E. Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis. Clin Sci 1957; 16:645–50.
   PubMed Web of Science ®Google Scholar
• Buckell M, Elliott FA. Diurnal fluctuation of plasma fibrinolytic activity in normal males. Lancet 1959;1:660–2.
   PubMed Web of Science ®Google Scholar
• Billimoria JD, Drysdale J, James DCO, Maclagan NF. Determination of fibrinolytic activity of whole blood with special reference to the effects of exercise and fat feeding. Lancet 1959;11:471–5.
   Google Scholar
• Cepelak V, Barcal R, Lang N, Cepelakova H. Zum Tag- und Nachtrhythmus der Fibrinolyse. Z Inner Med 1966;21:202–4.
   PubMedGoogle Scholar
• Cepelak V, Barcal R. Fibrinolysis in twins and its variation in circadian rhythm. Plzen Lek Sborn 1959;129:22.
   Google Scholar
• Mann RD. Effect of age, sex, and diurnal variation on the human fibrinolytic system. J Clin Puthol 1967;20:223–6.
   PubMed Web of Science ®Google Scholar
• Rosing DR, Brakman P, Redwood DR, et al. Blood fibrinolytic activity in man: diurnal variation and the response to varying intensities of exercise. Circ Res 1970;27:171–84.
   PubMed Web of Science ®Google Scholar
• Rosing DR, Redwood DR, Brakman P, Astrup T, Epstein SE. Impairment of the diurnal fibrinolytic response in man: effects of aging, type IV hyperlipoproteinemia and coronary artery disease. Circ Res 1973;32:752–7.
   PubMed Web of Science ®Google Scholar
• Korsan-Bengtsen K, Wilhelmsen L, Tibblin G. Blood coagulation and fibrinolysis in relation to degree of physical activity during work and leisure time. Acta Med Scand 1973;193:73–7.
   PubMedGoogle Scholar
• Kluft C. C 1-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis. Thromb Res 1978; 13: 135–51.
   PubMed Web of Science ®Google Scholar
• Kluft C, Jie AFH, Allen AR. Behaviour and quantitation of extrinsic (tissue-type) plasminogen activator in human blood. Thromb Haemost 1983;50518-23.
   Google Scholar
• KruithofEKO, Ransijn A, Bachmann F. Inhibition of tissue plasminogen activator by human plasma. In: Davidson JF, Bachmann F, Bouvier CA, Kruithof EKO, eds. Progress injibrinolysis, Vol. 4. Edinburgh: Churchill Livingstone, 1983:362–6.
   Google Scholar
• Kluft C, Verheijen JH, Rijken DC, Chang GTG, Jie AFH, Onkelinx C. Diurnal fluctuations in the activity of the fast-acting t-PA inhibitor. In: Davidson JF, Donati MB, Coccheri S, eds. Progress in jibrinolysis, Vol. 7. Edinburgh: Churchill Livingstone, 1985: 117–9.
   Google Scholar
• Neerstrand H, Ostergaard P, Bergqvist D, Matzsch T, Hedner MU. tPA inhibitor, tPAAg, plasminogen and alpha-2-antiplasmin after low molecular weight heparin or standard heparin. Fibrinolysis 1987;1:39–43.
   Google Scholar
• Andreotti F, Davies GJ, Hackett DR, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988;62:635–7.
   PubMed Web of Science ®Google Scholar
• Andreotti F, Davies GJ, Hackett D, et al. Circadian variation of fibrinolytic factors in normal human plasma. Fibrinolysis 1988;290-2.
   Google Scholar
• Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988;59:329–32.
   PubMed Web of Science ®Google Scholar
• Grimaudo V, Hauert J, Bachmann F, Kruithof EKO. Diurnal variation of the fibrinolytic system. Thromb Haemost 1988;59:495–9.
   PubMed Web of Science ®Google Scholar
• Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAL 1) Circulation 1989;79:101–6.
   Google Scholar
• Johansen LG, Gram J, Kluft C, Jespersen J. Chronobiology of coronary risk markers in Greenland Eskimos—a comparative study with Caucasians residing in the same Arctic area. Chronobiol Znt 1991;8:352–60.
   PubMed Web of Science ®Google Scholar
• Takada A, Takada Y, Urano T, Sakakibara K, Rydzewski A. Fluctuations of euglobulin lysis time, tissue plasminogen activator, and free and total plasminogen activator inhibitor levels in plasma in daytime. Thromb Res 199057:13–20.
   Google Scholar
• Aschoff J. Circadian rhythms: general features and endocrinological aspects. In: Martini L, Krieger DT, eds. Comprehensive endocrinology series. Endocrine rhythms. New York: Raven Press, 1979; 1–61.
   Google Scholar
• Peternel P, Stegnar U, Salobir B, Salobir D, Keber D, Vene N. Shift work and circadian rhythm of blood fibrinolytic parameters. Fibrinolysis 1990;4:113–5.
   Google Scholar
• Moore-Ede MC, Czeisler CA, Richardson GS. Circadian timekeeping in health and disease. Part 2. Clinical implications of circadian rhythmicity. N Engl J Med 1983;309:530–6.
   PubMed Web of Science ®Google Scholar
• Harenberg J, Weber E, Spohr U, Marl H. Is the diurnal increase of fibrinolytic activity influenced by alpha- or beta-adrenergic blockade? Hut 1980;41:455–8.
   Google Scholar
• Andreotti F, Kluft C, Davies GJ, Huisman LGM, de Bart ACW, Maseri A. Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1. Am J Cardiol (in press).
   Web of Science ®Google Scholar
• Ganong WF. Review of medical physiology, 9th edition. Los Altos: Lange Medical Publications, 1979:360.
   Google Scholar
• Palms L, Blennow G, Wetterberg L. Correction of non-24-hour sleeplwake cycle by melatonin in a blind retarded boy. Ann Neurol 1991;29:336–9.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Wollter IM, Christenson B, Stigendal L, Risberg B. Heparin and fibrinolysis-comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Thromb Hae-most 1988;59:284–8.
   PubMed Web of Science ®Google Scholar
• Jespersen J, Kluft C. Inhibition of tissue-type plasminogen activator in women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemost 1986;55:388–9.
   PubMed Web of Science ®Google Scholar
• Verheijen JH, Rijken DC, Chang GTG, Preston FE, Kluft C. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemost 1984;s 1:396–7.
   Google Scholar
• Jespersen J. The diurnal increase in euglobulin fibrinolytic activity in women using oral contraceptives and in normal women, and the generation of extrinsic fibrinolytic activity. Thromb Haemost 1986;56:183–8.
   PubMed Web of Science ®Google Scholar
• Andreotti F, Davies GJ, Maseri A, Kluft C. Inhibition of fibrinolysis in blood: circadian fluctuation and possible relevance to coronary artery disease. In: von Arnim T, Maseri A, eds. Predisposing conditions for acute ischaemic syndromes. Darmstadt: Steinkopff Verlag, 1989:20–32.
   Google Scholar
• Boyles PW. Fibrinolytic activity and thromboembolism. Clin Pharrnacol Ther 1972; 13:534–8.
   PubMed Web of Science ®Google Scholar
• Huber K, Rosc D, Resch 1, et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Huemost 1988;60:372–6.
   PubMed Web of Science ®Google Scholar
• Andreotti F, Roncaglioni MC, Hackett DR, et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor- I and von Willebrand factor in acute myocardial infarction. J Am Coll Curdiol 1990;16:1553–60,
   PubMed Web of Science ®Google Scholar
• Kluft C, Verheijen JH, Jie AFH, et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scund J Clin Lab Invest 1985;45:605–10.
   PubMed Web of Science ®Google Scholar
• Six AJ, Liem MK, Dooijewaard G, et al. The acute-phase reaction of the fibrinolytic system in acute myocardial infarction and unstable angina. Coronary Artery Dis (in press).
   Google Scholar
• Hajjar GC, Whissen NC, Moser KM. Diurnal variation in plasma euglobulin activity and fibrinogen levels. Angiology 1961;12:160–4.
   PubMed Web of Science ®Google Scholar
• Barcal R, Cepelak V, Cepelakova H, Lang N. The role of diurnal cycle in the blood clotting and fibrinolysis. Plzen Lek Sborn 1967; 18:71.
   Google Scholar
• Simpson HCR, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; I:786-90.
   Google Scholar
• Keegan AL, Holland CD, Jayson MIV. Loss of diurnal variation in fibrinolytic activity in systemic sclerosis. Br J Rheumatol 1985;24:211.
   Google Scholar
• Kluft C, Andreotti F. Consequences of the circadian fluctuation in plasminogen activator inhibitor 1 (PAI-1) for studies on blood fibrinolysis. Fihrinolysis 1988;2:93–5.
   Google Scholar
• Johansen LG, Gram J, Kluft C, Jespersen J. Circadian variation of extrinsic fibrinolytic components in blood from Eskimos. Fibrinolysis 1990;4:35–9.
   Google Scholar
• Menon SI, Smith PA, White RWB, Dewar HA. Diurnal variations of fibrinolytic activity and plasma-11-hydroxycorticosteroid levels. Lancet 1967;11:531–3.
   Google Scholar
• Chandler WL, Mornin D, Whitten RO, et al. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. Thromb Res 1990;58: 1- 12.
   Web of Science ®Google Scholar
• Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasrninogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988;263:5797–803.
   PubMed Web of Science ®Google Scholar
• Fujii S, Lucore CL, Hopkins WE, Billadello JJ, Sobel BE. Induction of synthesis of plasminogen activator inhibitor type- I and tissue-type plasminogen activator in human hepatic and endothelial cells. Thromb Haemost 199064:412–9.
   Google Scholar
• de Fouw NJ, van Hinsbergh VWM, de Jong YF, Haverkate F, Bertina RM. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Huemost 1987;57:176–82.
   PubMed Web of Science ®Google Scholar
• Okajima K, Koga S, Kaji M, et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Huemost 1990;63:48–53.
   PubMed Web of Science ®Google Scholar
• de Boer A, Kluft C, Cohen AF. Life style and blood fibrinolytic activity: a comment on clearance of plasminogen activators. Frbrinolysis 1990;4:61–3.
   Google Scholar
• Peternel P, Mozina H, Stegnar M, Keber D, Vene N. Reduced diurnal rhythm of fibrinolytic activity in patients with pace-maker. Fibrinolysis 1988;2(suppl l):7.
   Google Scholar
• Paramo JA, Colucci M, Collen D. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985;29:573–4.
   Google Scholar
• Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Euu Heart J 1989; 1077–82.
   Google Scholar
• Juhan-Vague I, Alessi MC, Joly P, et al. Plasma plasminogen activator inhibitor-I in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989;9:362–7.
   PubMedGoogle Scholar
• Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-I gene. Promoter and structural gene nucleotide sequences. JBiol Chem 1988;263:9129–41.
   PubMed Web of Science ®Google Scholar
• Petersdorf RG, Root RK. Disturbances of heat regulation. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, eds. Harrison's principles of internal medicine, 11th edition. New York: McGraw-Hill Book Company, 1987:44.
   Google Scholar
• Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol 1986;103:2403–10.
   PubMed Web of Science ®Google Scholar
• Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 199082: 1485–93.
   Google Scholar
• WHO International Study Group. Myocardial infarction community registers: public health in Europe, Vol. 5. Copenhagen: Regional Office for Europe (WHO), 1976:188–91.
   Google Scholar
• Muller JE, Ludrner PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiacdeath. Circulation 1987;75:131–8.
   PubMed Web of Science ®Google Scholar
• Behar S, Reicher-Reiss H, Goldbourt U, Kaplinski E, and Principal Investigators of SPRINT, Israel. Circadian variation in pain onset in unstable angina. Am J Cardiol 1991;67:91–3.
   PubMed Web of Science ®Google Scholar
• Marshall J. Diurnal variation in occurrence of strokes. Stroke 1977;88:230–1.
   Google Scholar